Overview

Study of Milnacipran for the Treatment of Fibromyalgia

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with fibromyalgia.
Phase:
Phase 3
Details
Lead Sponsor:
Forest Laboratories
Collaborator:
Cypress Bioscience, Inc.
Treatments:
Levomilnacipran
Milnacipran